Literature DB >> 9169821

Dynamics of tumor oxygenation, CD31 staining and transforming growth factor-beta levels after treatment with radiation or cyclophosphamide in the rat 13762 mammary carcinoma.

Y Kakeji1, Y Maehara, M Ikebe, B A Teicher.   

Abstract

PURPOSE: Tumors are dynamic tissues that undergo marked molecular, biochemical, and physiologic changes in response to cytotoxic anticancer therapies. Understanding the changes in tumor oxygenation and transforming growth factor-beta expression may allow improved treatment regimens to be developed. METHODS AND MATERIALS: The effects of a single dose of radiation therapy (20 Gy) or a single dose of chemotherapy (cyclophosphamide, 250 mg/kg) on several molecular and physiologic parameters of the rat 13762 mammary carcinoma growing subcutaneously in female Fischer 344 rats were explored.
RESULTS: Treatment of the tumor-bearing animals with 20 Gy of radiation killed about two logs (99%) of the 13762 tumor cells, and treatment with cyclophosphamide (250 mg/kg) killed about 1.5 logs (95%) of the 13762 tumor cells. Hypoxia, as determined by a pO2 electrode, initially decreased in the tumors of treated animals until 6 h. posttreatment and then increased, so that 24 h. after administration of the radiation therapy or the chemotherapy the number of intratumoral vessels as determined by CD31 staining increased until about 24 h after cytotoxic therapy. Transforming growth factor-beta1, measured by radioimmunoassay, peaked in the serum between 6 h and 18 h and again between 72 h and 96 h after radiation therapy and peaked in the tumor at 24 h and again at 72 h after radiation therapy. The first serum peak after cyclophosphamide was 3 h after drug injection, with second peaks at 36 h and 48 h after drug administration. In the tumor, transforming growth factor-beta1 peaked between 6 h and 8 h after drug administration and again 36 h and 72 h after drug. Apoptosis was maximal 6 h after 20 Gy and 24 h after cyclophosphamide. Vascular endothelial growth factor was also increased in tumors after cytotoxic therapy.
CONCLUSIONS: These changes in the tumor physiologic status are sufficient to protect the tumor from a second cytotoxic insult administered days afterwards and to result in a restructuring of the tissue.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9169821     DOI: 10.1016/s0360-3016(96)00573-1

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  14 in total

Review 1.  Radiation therapy and immunotherapy: what is the optimal timing or sequencing?

Authors:  Maureen L Aliru; Jonathan E Schoenhals; Bhanu P Venkatesulu; Clark C Anderson; Hampartsoum B Barsoumian; Ahmed I Younes; Lakshmi S K Mahadevan; Melinda Soeung; Kathryn E Aziz; James W Welsh; Sunil Krishnan
Journal:  Immunotherapy       Date:  2018-02-01       Impact factor: 4.196

Review 2.  The Kraken Wakes: induced EMT as a driver of tumour aggression and poor outcome.

Authors:  Andrew D Redfern; Lisa J Spalding; Erik W Thompson
Journal:  Clin Exp Metastasis       Date:  2018-06-08       Impact factor: 5.150

3.  HIF-1-dependent stromal adaptation to ischemia mediates in vivo tumor radiation resistance.

Authors:  David L Schwartz; James Bankson; Luc Bidaut; Yi He; Ryan Williams; Robert Lemos; Arun Kumar Thitai; Junghwan Oh; Andrei Volgin; Suren Soghomonyan; Hsin-Hsien Yeh; Ryuichi Nishii; Uday Mukhopadhay; Mian Alauddin; Ioseb Mushkudiani; Norihito Kuno; Sunil Krishnan; William Bornman; Stephen Y Lai; Garth Powis; John Hazle; Juri Gelovani
Journal:  Mol Cancer Res       Date:  2011-03-01       Impact factor: 5.852

4.  Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human breast cancer and ovarian cancer xenografts.

Authors:  Beverly A Teicher; Krishna Menon; Enrique Alvarez; Chuan Shih; Margaret M Faul
Journal:  Invest New Drugs       Date:  2002-08       Impact factor: 3.850

Review 5.  Biologically conformal treatment: biomarkers and functional imaging in radiation oncology.

Authors:  Yaacov Richard Lawrence; Maria Werner-Wasik; Adam P Dicker
Journal:  Future Oncol       Date:  2008-10       Impact factor: 3.404

6.  Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias.

Authors:  Constantine S Mitsiades; Cecile Rouleau; Cinara Echart; Krishna Menon; Beverly Teicher; Maria Distaso; Antonio Palumbo; Mario Boccadoro; Kenneth C Anderson; Massimo Iacobelli; Paul G Richardson
Journal:  Clin Cancer Res       Date:  2009-02-15       Impact factor: 12.531

7.  Autocrine pathways of the vascular endothelial growth factor (VEGF) in glioblastoma multiforme: clinical relevance of radiation-induced increase of VEGF levels.

Authors:  Hans-Herbert Steiner; Sybille Karcher; Margareta M Mueller; Emilios Nalbantis; Stefan Kunze; Christel Herold-Mende
Journal:  J Neurooncol       Date:  2004-01       Impact factor: 4.130

8.  Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression.

Authors:  Swati Biswas; Marta Guix; Cammie Rinehart; Teresa C Dugger; Anna Chytil; Harold L Moses; Michael L Freeman; Carlos L Arteaga
Journal:  J Clin Invest       Date:  2007-04-05       Impact factor: 14.808

Review 9.  TGFβ-Directed Therapeutics: 2020.

Authors:  Beverly A Teicher
Journal:  Pharmacol Ther       Date:  2020-08-21       Impact factor: 12.310

Review 10.  Transforming growth factor-beta in breast cancer: too much, too late.

Authors:  Mary Helen Barcellos-Hoff; Rosemary J Akhurst
Journal:  Breast Cancer Res       Date:  2009-02-26       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.